Data from FDA - Curated by Toby Galbraith - Last updated 19 May 2017

Licensing authority

FDA (Food and Drug Administration, USA)


Alphanate is an Antihemophilic Factor/von Willebrand Factor Complex (Human) indicated for:
• Control and prevention of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency (1.1)
• Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery (1.2)

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Related Content

Advisory information

• Patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components (4)
Special warnings and precautions

• Anaphylaxis and severe hypersensitivity reactions are possible. Should symptoms occur, treatment with Alphanate should be
discontinued, and emergency treatment should be sought (5.1)
• Development of activity-neutralizing antibodies has been detected in patients receiving FVIII containing products. Development of alloantibodies to VWF in Type 3 VWD patients have been occasionally reported in the literature (5.2)
• Thromboembolic events may be associated with AHF/VWF Complex (Human) in VWD patients, especially in the setting of known risk factors (5.3)
• Intravascular hemolysis may be associated with infusion of massive doses of AHF/VWF Complex (Human) (5.4)
• Rapid administration of a FVIII concentrate may result in vasomotor reactions (5.5)
• Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk (5.6)

Adverse reactions

The most frequent adverse events reported with Alphanate in > 5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue (6).

Usage information

Dosing and administration
For Intravenous use only.
Alphanate contains the labeled amount of Factor VIII expressed in International Units (IU) FVIII/vial and Willebrand
Factor:Ristocetin Cofactor activity in IU VWF:RCo/vial (2).

Hemophilia A: Control and prevention of bleeding episodes (2.1)
• Dose (units) = body weight (kg) x desired FVIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)
• Frequency of intravenous injection of the reconstituted product is determined by the type of bleeding episode and the recommendation of the treating physician

von Willebrand Disease: Surgical and/or invasive procedure in adult and pediatric patients except Type 3 undergoing major surgery (2.2)
• Adults: Pre-operative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg/body weight at 8-12 hour intervals post-operative as clinically needed.
• Pediatric: Pre-operative dose of 75 IU VWF:RCo/kg/body weight; subsequent doses of 50-75 IU VWF:RCo/kg body weight at 8-12 hour intervals post-operative as clinically needed.
• Dosage based on protocol used in the Alphanate prospective clinical trial according to judgment of the investigator.
Use in special populations
• Pregnancy: No human or animal data. Use only if clearly needed (8.1)
• Labor and Delivery: No human or animal data. Use only if clearly needed (8.2)
• Nursing Mothers: No human or animal data. Use only if clearly needed (8.3)
• Pediatric Use: Clinical trials for safety and effectiveness in pediatric hemophilia A patients have not been conducted. The hemostatic efficacy of Alphanate has been studied in 20 pediatric subjects with VWD 18 years of age and under. Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo (8.4).
• Geriatric Use: No human or animal data. Use only if clearly needed (8.5)

More information

Category Value
Authorisation number BLA102475
Orphan designation No
Product NDC 68516-4601; 68516-4602; 68516-4603; 68516-4604; 68516-4609
Date First Approved 31-01-2007
Date Last Revised 19-05-2017
Marketing authorisation holder Grifols Biologicals Inc